MRD Monitoring in Acute Myeloid Leukemia mr d technology

by adminhuahinsunvilla3sd



Minimal residual disease (MRD) after therapy has unequivocal prognostic value in acute myeloid leukemia. There is growing evidence that the presence of MRD detected by multiparametric flow cytometry (MFC) and quantitative polymerase chain reaction (qPCR)-based methods, has improved the assessment of treatment response and risk stratification for clinical management. New molecular methods, such as high-throughput next-generation sequencing (NGS), have evolved into routine laboratory tools to improve the sensitivity and specificity of MRD detection. In this talk, Dr. Chen reviews the methodological approaches of MRD detection, discusses the clinical implications of MRD in risk stratification and suggests potential areas for future investigation.

After viewing this lecture, participants should be able to:
1. Describe the methodological principles of minimal residual disease testing in acute myeloid leukemia.
2. Recognize the advantages and limitation of different methods for minimal residual disease testing.
3. Discuss the implications of minimal residual disease in prognosis and treatment of acute myeloid leukemia.

Xueyan Chen, MD, PhD, assistant professor, Department of Laboratory Medicine, associate director, Hematopathology Laboratory, UW

10/10/2017

.

Images related to the topic mr d technology

MRD Monitoring in Acute Myeloid Leukemia

MRD Monitoring in Acute Myeloid Leukemia

Search related to the topic MRD Monitoring in Acute Myeloid Leukemia

#MRD #Monitoring #Acute #Myeloid #Leukemia
MRD Monitoring in Acute Myeloid Leukemia
mr d technology
You can see a lot of useful information here: See more here
You can see a lot of useful information here: See more here

Related Posts

Leave a Comment